Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoSABR: L19-IL2 + SABR in Metastatic NSCLC
NCT03705403Phase 2Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2019
- Primary completion
- Jan 2025
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 2 trial of darleukin in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Started Apr 2019; status: terminated.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03705403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705403.